SEC Form 4 · accession 0001127602-16-038513
Elevance Health, Inc. · ELV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Swedish
Officer — Chair, President & CEO · Director
Period of report
Jan 28, 2016
Accepted (ET)
Jan 29, 2016 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001156039
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 28, 2016 | S | 3,329 | $127.83 | D | 190,899 | D | |
| Common StockF3 | Jan 28, 2016 | S | 3,100 | $128.86 | D | 187,799 | D | |
| Common StockF4 | Jan 28, 2016 | S | 2,000 | $129.66 | D | 185,799 | D | |
| Common StockF5 | Jan 28, 2016 | S | 1,839 | $131.25 | D | 183,960 | D | |
| Common StockF6 | Jan 28, 2016 | S | 1,258 | $132.10 | D | 182,702 | D | |
| Common Stock | Jan 28, 2016 | S | 100 | $132.79 | D | 182,602 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2015.
- F2This transaction was executed in multiple trades at prices ranging from $127.31 to $128.13. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $128.33 to $129.30. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $129.33 to $130.27. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $130.71 to $131.65. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $131.73 to $132.50. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.